BPTF is overexpressed in NSCLC and is associated with poor prognosis [134,135], and as cisplatin is a mainstay of NSCLC therapy, it will be important moving forward to determine if expression of either NSUN2 or BTPF is associated with resistance to cisplatin. This evidence concerns the gene BPTF and non-small cell lung carcinoma.